1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL)

Staff Training, Qualifications & Delegation of Authority Log (DOAL)

Core Regulatory Mandate: Under ICH E6(R3) Annex 1 section 2.3.1, "The investigator is responsible for supervising any individual or any party to whom the investigator delegates trial-related duties and functions conducted at the trial site." Under Section 4.2.6, "If the investigator/institution retains the services of any individual or party to undertake trial-related duties and functions, the investigator/institution should ensure that this individual or party is qualified... and should ensure an integrity system is maintained."

Failure to properly delegate, train, and supervise trial site personnel is the single most common category of FDA Form 483 observations and Warning Letters issued to clinical investigators. Master the mechanics of the Delegation of Authority Log (DOAL), qualification verification, and training workflows.

---

1. Anatomy of the Delegation of Authority Log (DOAL)

The Delegation of Authority Log (DOAL) (also termed the Site Delegation Log, Signature and Delegation Log, or Responsibility Log) is a living regulatory document maintained within the Investigator Site File (ISF).

┌───────────────────────────────────────────────────────────────────────────┐
│                      MANDATORY DOAL ELEMENTS                              │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Protocol Identification: Protocol number, title, and site number      │
│  2. Principal Investigator Name & Signature: Confirms site leadership     │
│  3. Staff Member Details: Full printed name and institutional role        │
│  4. Standardized Task Assignment Codes: Specific authorized activities     │
│  5. Specimen Signature & Initials: To authenticate paper/eSource entries  │
│  6. Task Start Date: Must be ON or BEFORE any protocol task is performed  │
│  7. Task End Date: Mandatory when a staff member departs or changes roles │
│  8. PI Authorization Signature & Date: Confirms prospective delegation    │
└───────────────────────────────────────────────────────────────────────────┘

The Cardinal Rule: Prospective Authorization

Delegation is prospective, never retroactive.

• Step 1: Staff member submits CV, active medical license, and GCP certificate.
• Step 2: Staff member completes protocol-specific training (documented on training log).
• Step 3: Staff member signs and initials the DOAL.
• Step 4: Principal Investigator signs and dates the DOAL authorizing the specific tasks.
• Step 5: Staff member may now perform the delegated tasks.

Inspection Pitfall: If a study coordinator obtains informed consent on August 10th, but the PI did not sign and date the DOAL authorizing that coordinator for consent until August 15th, an auditor will cite unauthorized conduct of research / invalid consent execution.

---

2. Standardized Task Codes & Scope of Practice

Delegation must align strictly with the individual's licensure, institutional credentials, education, and legal scope of practice. A PI cannot delegate a task to an individual who is not legally qualified to perform it under state or national law, regardless of their protocol-specific training.

---

3. Essential Staff Qualifications & Documentation

For every individual listed on the DOAL, the Investigator Site File (ISF) must contain verifiable proof of competence before that individual engages in trial activities:

┌───────────────────────────────────────────────────────────────────────────┐
│                     MANDATORY CREDENTIALS IN THE ISF                      │
├───────────────────────────────────────────────────────────────────────────┤
│  • Signed & Dated Curriculum Vitae (CV): Current (updated within 2 years)  │
│  • Active Professional Licensure: Verified MD, DO, RN, NP, PA, RPh licenses│
│  • Good Clinical Practice (GCP) Training: TransCelerate-recognized cert    │
│  • Human Subjects Protection (HSP) Training: CITI / NIH / Institutional   │
│  • Protocol-Specific Training Log: Signed on current protocol version     │
│  • Role-Specific Certifications: IATA Dangerous Goods, BLS/ACLS, Lab Certs│
└───────────────────────────────────────────────────────────────────────────┘

Documenting Protocol Amendments

When a sponsor issues a protocol amendment (e.g., changing dosing schedules, adding new safety labs, or altering inclusion criteria):

1. All active site personnel must be retrained on the amended protocol.
2. A new Protocol Training Log must be signed and dated by all staff prior to managing subjects under the amended protocol.
3. The PI must verify that the IRB has approved the amendment before implementing changes.

---

4. Managing Site Staff Turnover

Staff turnover is a major vulnerability during multi-year clinical trials. Sites must implement a rigorous Standard Operating Procedure (SOP) whenever personnel depart or new personnel join.

┌───────────────────────────────────────────────────────────────────────────┐
│                    STAFF TURNOVER REMEDIATION WORKFLOW                    │
├───────────────────────────────────────────────────────────────────────────┤
│  DEPARTING STAFF:                                                         │
│  1. Enter exact "End Date" on the DOAL.                                   │
│  2. PI initials/dates the departure entry.                                │
│  3. Notify Sponsor/CRO to deactivate user accounts in EDC, IVRS, and eTMF.│
│  4. Conduct handover meeting and reallocate active subjects.              │
│                                                                           │
│  NEW REPLACEMENT STAFF:                                                   │
│  1. Collect and file signed CV, active license, and GCP/HSP certificates. │
│  2. Complete comprehensive protocol and system-specific training.         │
│  3. Enter new staff details, task codes, and specimen signature on DOAL.  │
│  4. PI signs and dates authorization line (PROSPECTIVE GREENLIGHT).       │
│  5. Request system credentials from Sponsor/CRO.                          │
└───────────────────────────────────────────────────────────────────────────┘

---

Realistic Clinical Scenario: The Retrospective Delegation Trap

Scenario: A clinical trial site is conducting a Phase III diabetes study. The primary study coordinator goes on emergency medical leave. The PI hires an experienced research nurse, Nurse Jenkins, who holds active RN licensure and current GCP certification. On her first day (October 1st), Nurse Jenkins conducts Visit 4 for Subject 108, performing informed consent for an amended protocol, obtaining vital signs, drawing PK blood, and entering data into the EDC system. On October 10th, the PI conducts his bi-weekly site visit, reviews Nurse Jenkins' work, adds her to the DOAL with a start date backdated to October 1st, and signs the log.

Audit & Inspection Findings:

1. Unqualified/Unauthorized Consent & Study Conduct: Between October 1st and October 10th, Nurse Jenkins performed trial tasks without documented protocol training and without prospective PI delegation authorization.
2. Backdating / Data Integrity Violation: The PI's backdating of the DOAL constitutes a deliberate documentation violation.
3. Inspection Result: During a BIMO (Bioresearch Monitoring) inspection, the FDA investigator issues a Form FDA 483 citation for failure to supervise the study and failure to ensure proper informed consent execution.